Trial Profile
A Phase I, Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Lamivudine in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Dolutegravir/lamivudine (Primary) ; Dolutegravir; Lamivudine
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors ViiV Healthcare
- 12 Jul 2016 Status changed from recruiting to completed.
- 06 Jun 2016 Status changed from not yet recruiting to recruiting.
- 20 Apr 2016 New trial record